Anti-TNF-α antibody, its products and applications
By constructing a canine natural bacteriophage antibody library screening and modification, high-affinity canine-derived monoclonal antibodies F6 and G5 were obtained, which solved the problem of human antibodies causing immune response in canines, and achieved effective neutralization and therapeutic effects on dog TNF-α.
Patent Information
- Application Number
- CN202411612661.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-12
- Publication Date
- 2025-07-25
- Estimated Expiration
- 2044-11-12
AI Technical Summary
In the prior art, human anti-TNF-α antibodies will cause severe immune response when applied to canines, resulting in lower efficacy than expected, and lack of TNF-α antibodies that are highly effective specifically targeted to canines.
A canine natural bacteriophage antibody library was constructed, and specific targets were screened for canine inflammatory bowel disease were screened out. High-affinity canine-derived monoclonal antibodies F6 and G5 were obtained through antibody engineering to block the binding of dog TNF-α to its receptor.
The canine-derived monoclonal antibodies F6 and G5 show significant neutralization ability, can effectively block inflammatory signaling pathways, significantly improve the symptoms of inflammatory bowel disease related to dog TNF-α, and in vivo experiments have shown good therapeutic effects.